• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

Advertisement

Document › Details

Biofrontera AG. (2/3/12). "Press Release: Biofrontera AG – 500,000 Shares Subscribed in Capital Increase". Leverkusen.

	Organisation	Biofrontera AG
	Group	Biofrontera (Group)
	Product	Ameluz®
	Product 2	investment banking
	Index term	Biofrontera–SEVERAL: investment, 201202 private placement capital increase €1.5m 500k new shares
	Person	Pehlemann, Werner (Biofrontera 200601– CFO before own firm + Dresdner Bank)

Ad-hoc Release pursuant to Section 15 of the German Securities Trading Act (Wertpapierhandelsgesetz)


Management and supervisory board of Biofrontera AG have decided to increase the company's base capital from EUR 11,240,486.00 by up to Euro 500,000.00 to up to EUR 11,740,486.00 through issuing 500,000 new ordinary shares from authorized capital II. The purchase right of the shareholders was excluded. According to today's tabulation, the private placement of the shares was successfully completed and over-subscribed. The registration of the shares will follow shortly. The proceeds of the capital increase amount to about € 1.5 mln.

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611


Contact:

Werner Pehlemann
Biofrontera AG
Tel.: +49 (0214) 87 63 20, Fax.: +49 (0214) 87 63 290
E-mail: w.pehlemann@biofrontera.com

Record changed: 2012-02-07

More documents for Biofrontera (Group)

• [1] Biofrontera AG. (4/4/12). "Press Release: Biofrontera and Bipharma Sign Exclusive Marketing and Distribution Agreement for Ameluz for the Benelux". Leverkusen....
• [2] Biofrontera AG. (3/30/12). "Press Release: Biofrontera Publishes Financial Report 2011". Leverkusen....
• [3] Biofrontera AG. (3/29/12). "Press Release: Biofrontera and Allergan Sign Marketing and Distribution Agreement for Ameluz in Spain". Leverkusen....
• [4] AB (ARD). (3/26/12). "Pressemitteilung: Maschmeyers nächster Streich. Elektro-Fahrräder, eine Pflegeklinik und nun Biotechnologie"....
• [5] Biofrontera AG. (3/23/12). "Press Release: Biofrontera AG – 4,402,682 Shares Subscribed in Capital Increase [Ad hoc release]". Leverkusen....
• [6] Biofrontera AG. (3/2/12). "Press Release: Ad hoc. Biofrontera AG Decides on Capital Increase". Leverkusen....
• [7] Biofrontera Pharmaceuticals GmbH. (2/6/12). "Press Release: Biofrontera and Desitin Sign Marketing and Distribution Agreement for Ameluz in Scandinavia". Leverkusen & Hamburg....
• [8] Biofrontera AG. (2/1/12). "Press Release: Biofrontera’s Ameluz as of Today Available in All German Pharmacies". Leverkusen....
• [9] Biofrontera AG. (12/16/11). "Press Release: European Commission Authorizes EU-wide Marketing and Distribution of Biofrontera’s Ameluz (Ad hoc in accordance with sec. 15 WpHG)". Leverkusen....
• [10] Biofrontera AG. (12/7/11). "Press Release: Biofrontera AG Emits New Partial Debentures of Its 5% Option Bond 2011/2016 [Ad hoc in accordance with sec. 15 WpHG]". Leverkusen....

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our free web portals Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

» top

» Imprint  |  » Contact  |  The use of this website requires to accept the disclaimer!   |  A project of [iito] Business Intelligence © 2002-2012. Made in Germany.